Skip to content

Trevi Therapeutics

US · TRVI #2810 by market cap Listed 2019
13.35 -0.37 -2.70%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions increased by 5 in the most recent period (2026/Q3).
  • Total institutional ownership rose 3.4 percentage points.

Ownership vs. money flow

Aligned

Institutions added shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two line up.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
111.77% +3.43pp
Institutions
260 +5
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund57.69%
VC/PE Fund29.46%
Hedge Fund18.70%
Public Company3.89%
Private Company0.79%
Individual/Insider0.70%
Family Office/Trust0.40%
Insurance Company0.33%
Government Pension Fund0.28%

Top holders as of 2026-09-30

FMR 9.56% · 13.63M sh
New Enterprise Associates, Inc. 9.28% · 13.22M sh
BlackRock 8.62% · 12.29M sh
Frazier Life Sciences Management, LP 6.97% · 9.94M sh
Vanguard Capital Management, LLC 4.29% · 6.11M sh
Wellington Management Group 3.99% · 5.68M sh
Vivo Capital, LLC 3.57% · 5.09M sh
Woodline Partners LP 2.86% · 4.08M sh
Assenagon Asset Management S.A. 2.47% · 3.53M sh
MPM BioImpact LLC 2.16% · 3.07M sh
Vestal Point Capital, LP 2.18% · 3.10M sh
State Street Global Advisors 2.30% · 3.27M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 38 buys · 12 sells

NameRoleStake
David Meeker Independent Chairperson 0.25%
Thomas Sciascia Co-Founder & CSO 0.16%
Jennifer Good Co-Founder, CEO, President, & Director 0.15%
Farrell Simon Chief Commercial Officer 0.06%
Lisa Delfini Former Chief Financial Officer 0.05%
Christopher Galletta Controller & Chief Accounting Officer 0.02%
Anne VanLent Independent Director 0.02%
Michael Heffernan Independent Director 0.00%
New Enterprise Associates, Inc. -- --
James Cassella Chief Development Officer --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-14 Michael Heffernan Independent Director Derivative Exercise and Sale -39,473 $3.04–15.88
2026-06-02 Anne VanLent Independent Director Other Derivative Acquisition +35,000 $13.45
2026-06-02 Dominick Colangelo Independent Director Other Derivative Acquisition +35,000 $13.45
2026-06-02 Edward Mathers Independent Director Other Derivative Acquisition +35,000 $13.45
2026-06-02 David Meeker Independent Chairperson Other Derivative Acquisition +35,000 $13.45
2026-06-02 Michael Heffernan Independent Director Other Derivative Acquisition +35,000 $13.45
2026-02-18 James Cassella Chief Development Officer Other Derivative Acquisition +215,000 $10.56
2026-02-18 Jennifer Good Co-Founder, CEO, President, & Director Other Derivative Acquisition +675,000 $10.56
2026-02-18 Thomas Sciascia Co-Founder & CSO Other Derivative Acquisition +85,000 $10.56
2026-02-18 Christopher Galletta Controller & Chief Accounting Officer Other Derivative Acquisition +35,000 $10.56
2026-02-18 Farrell Simon Chief Commercial Officer Other Derivative Acquisition +160,000 $10.56
2026-01-07 David Hastings Chief Financial Officer & Principal Financial Officer Other Derivative Acquisition +375,000 $11.21
2025-12-01 Christopher Galletta Controller & Chief Accounting Officer Derivative Exercise and Retained +4,225 $0.51
2025-10-06 Lisa Delfini Former Chief Financial Officer Intent to Sell (Form 144) -108,650 $9.50
2025-10-02 Lisa Delfini Former Chief Financial Officer Intent to Sell (Form 144) -40,000 $9.67
2025-08-26 Lisa Delfini Former Chief Financial Officer Intent to Sell (Form 144) -312,855 $8.09
2025-06-10 Anne VanLent Independent Director Other Derivative Acquisition +45,000 $6.25
2025-06-10 Dominick Colangelo Independent Director Other Derivative Acquisition +45,000 $6.25
2025-06-10 Edward Mathers Independent Director Other Derivative Acquisition +45,000 $6.25
2025-06-10 David Meeker Independent Chairperson Other Derivative Acquisition +45,000 $6.25

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 20:02:43 · For reference only, not investment advice and not tailored to your situation.

Trevi Therapeutics discussion 0 comments

Add a comment